(Adnkronos) - Via libera dell’Agenzia italiana del farmaco (Aifa) alla rimborsabilità di finerenone, nuovo farmaco per il trattamento della malattia renale cronica in stadio 3 e 4, associata a diabete di tipo 2 in pazienti adulti con presenza di albuminuria, in aggiunta allo standard di cura. L’annuncio dell’ottenuta rimborsabilità del farmaco, primo antagonista selettivo non steroideo dei recettori dei mineralcorticoidi (MR) in grado di inibire la trascrizione dei geni pro-infiammatori e profibrotici, è stato dato da Bayer con la conferenza stampa ‘Verso un futuro senza dialisi’, svoltasi a Milano.
Category
🗞
NewsTranscript
00:00In Italy, 40% of diabetic patients have a chronic renal disease that leads to gradual
00:10renal damage, hypertension and cardiovascular problems to reach the terminal stage of the
00:15disease, i.e. dialysis or transplant.
00:17Today, thanks to FineRenone, which has obtained the free route of Haifa to reimbursement, patients
00:22with chronic renal disease associated with type 2 diabetes have a new therapeutic option
00:27that shows an anti-inflammatory and anti-fibrotic effect in the brain, heart and vases.
00:32The press conference talked about it towards a future absence of Bayer's dialysis.
00:37In addition to the inhibitor acids, the receptor antagonist of angiotensin, which we already
00:41know, there are the SGLT2, which are primary pharmaceuticals, and today we have the possibility
00:47of adding the FineRenone.
00:49This receptor antagonist of the corticosteroid hormone, which, however, is not steroid,
00:55has an anti-fibrotic, anti-protein, anti-progression effect of the renal disease and therefore
01:05it is a very important weapon that we have recently available to add it, obviously,
01:13to what we already have.
01:15FineRenone is the first non-steroidal selective antagonist of the receptors of corticosteroid
01:20minerals.
01:21The advantage of this new receptor antagonist is that it has a completely different structure
01:27and this means that it determines, following the bond with the receptor of these hormones,
01:34stimuli at the level of cytokines, of pro-inflammatory and pro-fibrotic substances of the inhibitor type.
01:43To confirm the effectiveness and safety of FineRenone, the Fidelio Registration Study.
01:48The Fidelio Study has shown that FineRenone is able to slow down the progression of renal
01:56damage in patients at very high risk and at high risk, in particular patients with a
02:03clearance between 25 and 75, with an albuminuria, an ACR between 30 and 5,000 mg.
02:12With FineRenone, Bayer enters a new therapeutic area, that of nephrology.
02:17It is very important because we have a history of research in various therapeutics and I think
02:24that our cardiovascular partnership is known to everyone.
02:28And today, finally, we also start to take care of the kidney, which we know is one of the
02:35most important organs in our body.
02:37And therefore, with FineRenone, we offer a concrete solution to the scientific community,
02:43but above all to Italian patients who need it the most.